What does Purslane do?#
A leave-on serum with purslane — Portulaca oleracea, a low-growing leafy plant eaten as a vegetable across much of the world. On skin it is a conditioning ingredient: it helps skin feel comfortable and hydrated and calms the look of redness.
Benefits
- Gentle enough for daily use — it scored zero for irritation in patch testing, and a three-week whole-face study recorded no product-related irritation in a group where most people had sensitive skin
- Helps skin feel comfortable and look less flushed
- Fine to use every day, morning or evening, with no easing-in period
- Layers with acids and retinol without adding to the load — it is not an exfoliant, so there is nothing to stack
How it works
Purslane is a leafy plant that has been eaten as a vegetable for centuries. Regulators list it as a skin-conditioning ingredient, and that is the level the evidence sits at: the published studies test whole creams and masks carrying several calming ingredients at once, so what the purslane itself contributed cannot be separated out. The best-controlled study of the group found the purslane cream well tolerated and improved from where it started — but no better than the cream it was compared against.
What to expect
Most people have no break-in phase and nothing to work through — no sting, no tingle, and feel nothing at all when they start. If a product containing purslane does bother you, that points at the rest of the formula rather than at this ingredient.
How to use Purslane#
Best time
Morning or evening — nothing in the record restricts it to one end of the day, and it does not make skin more sensitive to daylight.
Where it goes
A serum carrying it goes on after cleansing and before your moisturiser.
Where to apply
All over the face, and the eye area is included — that is how it was applied in the study its safety record rests on. Keep it out of the eye itself, as with any leave-on.
How to apply
A thin, even layer. Daily is fine, and twice daily is the pattern the studies used.
Alongside others
It sits alongside acids and retinol without adding to the load, because it is not an exfoliant. In the published studies it is repeatedly the step that comes after the harsher one rather than instead of it.
What to expect
Nothing, and that is the honest answer. Most people have no break-in phase, no sting and no tingle when they start.
What to look for
Names on a label matter here more than usual. The fermented version is a separate ingredient with its own record, and Portulaca pilosa is a different plant that is also sometimes called purslane. In a rinse-off cleanser it appears only as a trace, far below the amounts anyone has studied, so this is an ingredient to look for in something you leave on.
If it doesn't suit
If redness or itching appears, the rest of the formula is the more likely cause. In the one published case of a reaction to a purslane serum, the person was tested against all fifteen ingredients in the bottle: a different one was responsible and purslane was negative. Stop the product, let skin settle, and reintroduce things one at a time.
Discontinue use if unexpected discomfort occurs.
The form you will see it in
Purslane soothing serum
- Where it goes
- Before moisturizer
Using Purslane with other ingredients
What not to use with Purslane
Nothing flagged. None of the ingredients this wiki covers needs to be kept apart from Purslane — check the label of anything not covered here.
Who should avoid Purslane?#
Six situations change whether Purslane suits your skin right now. Each one is either a reason to skip it, a reason to go slowly, or nothing to watch for.
- Maternity & Nursing
- Go slowly
- Fragile or Sensitive
- No caution
- Recent Facial or Laser
- No caution
- Prone to Redness
- No caution
- Dry or Itchy Patches
- No caution
- Recent Shave or Wax
- No caution
Maternity & Nursing — If you are pregnant or nursing, you may prefer to check with your healthcare provider before use.
Cosmetic strength limits for Purslane where you live#
| Region | Most a cosmetic may contain | |
|---|---|---|
| No explicit cap | ||
The FDA restricts a short list of ingredients and sets no general strength ceiling on the rest. A figure marked "guidance, not law" is the Cosmetic Ingredient Review panel's recommendation. 21 CFR part 700, subpart B — Requirements for Specific Cosmetic Products (FDA) | ||
| No explicit cap | ||
One list does the work — Health Canada's Hotlist of prohibited and restricted cosmetic ingredients. | ||
| No explicit cap | ||
The Cosmetics Regulation's annexes, consolidated to 1 May 2026. A figure marked "guidance, not law" comes from the EU's cosmetic safety committee rather than from the annexes. | ||
| No explicit cap | ||
Great Britain kept the annexes as its own law and updates them only when it chooses; Northern Ireland follows the live EU Regulation, which is why some rows read differently for each. Regulation (EC) No 1223/2009 as it applies in Great Britain · Regulation (EC) No 1223/2009, Annexes II–VI | ||
| No explicit cap | ||
India writes its own standard, aligned to the European rules as they stood in 2012. Mandatory since 9 February 2026. IS 4707 (Part 2):2025 — restricted and prohibited cosmetic ingredients · IS 4707 (Part 3):2025 — preservatives · Cosmetics Rules, 2020, Ninth Schedule | ||
| No explicit cap | ||
ANVISA rewrote its restricted list in June 2026, and a companion act amended the prohibited list at the same time. RDC 1.029/2026 — restricted ingredients · RDC 529/2021 — prohibited ingredients, as amended by RDC 1.030/2026 · RDC 528/2021 — preservatives | ||
| No explicit cap | ||
Japan's cosmetics standard keeps drug ingredients out of cosmetics, so most of its figures sit in the ministry's list of the ones a cosmetic may still contain. Cosmetics Standards (化粧品基準), Ministry of Health, Labour and Welfare · Cosmetics Standards — the ministry's own English translation · Drug ingredients permitted in cosmetics — 2007 notification | ||
| No explicit cap | ||
One MFDS regulation carries both the prohibited list and the restricted list, in force 18 March 2026. Sunscreens and a few other categories are cleared product by product instead. Regulation on Safety Standards for Cosmetics (MFDS Notification 2026-19) · Regulation on the Review of Functional Cosmetics (MFDS Notification 2025-88) | ||
| No explicit cap | ||
Kenya's standard applies the EU annexes as they stand rather than copying them, so its ingredient limits are the EU's — including the 2024 additions. A figure marked "guidance, not law" sits outside the annexes and does not carry over. KS EAS 377-1, -2 and -3:2022 — cosmetics safety requirements, published by KEBS · Regulation (EC) No 1223/2009, Annexes II–VI | ||
| No explicit cap | ||
Namibia sets no ingredient limits at all. Its cosmetic rule is a single line requiring a product to be free of any harmful ingredient. Foodstuffs, Cosmetics and Disinfectants Ordinance 18 of 1979, and the regulations under it | ||
| No explicit cap | ||
Ukraine's own transposition of the EU annexes, as they stood before the 2024 additions, fully in force since 3 August 2026. A further revision is due on 1 February 2027. Technical Regulation on cosmetic products — Cabinet Resolution No. 65 of 20 January 2021 | ||
| No explicit cap | ||
Georgia has no cosmetics rulebook — its register of technical regulations carries no cosmetics entry — so only the general product-safety duty applies. | ||
| No explicit cap | ||
Australia writes no cosmetic ingredient list. A figure here is the point at which a substance becomes a medicine or a scheduled substance carrying Caution labelling, so its numbers sit well above other markets'. Poisons Standard — June 2026 · Therapeutic Goods (Excluded Goods) Determination 2018 | ||
| No explicit cap | ||
The Gulf standard points at the EU annexes as amended, so its ingredient limits are the EU's. A figure marked "guidance, not law" sits outside the annexes and does not carry over. GSO 1943:2024 — Cosmetic products: safety requirements (Gulf technical regulation) · Regulation (EC) No 1223/2009, Annexes II–VI | ||
| No explicit cap | ||
The Gulf standard points at the EU annexes as amended, so its ingredient limits are the EU's. A figure marked "guidance, not law" sits outside the annexes and does not carry over. GSO 1943:2024 — Cosmetic products: safety requirements (Gulf technical regulation) · Regulation (EC) No 1223/2009, Annexes II–VI | ||
| No explicit cap | ||
Hong Kong writes no cosmetics rulebook. Its Poisons List (Cap. 138A, Schedule 10) decides which substances may be sold only as medicines, and general safety is judged case by case against whichever overseas standard the enforcer considers reasonable. Pharmacy and Poisons Regulations (Cap. 138A), Schedule 10 — the poisons list · Pharmacy and Poisons Board — Guidance Notes on classifying pharmaceutical products, April 2026 | ||
| No explicit cap | ||
Singapore writes the ASEAN annexes into its own schedule, and its regulator tells companies to check the current ASEAN release as well — which is why a figure here can read "guidance, not law". Health Products (Cosmetic Products — ASEAN Cosmetic Directive) Regulations 2007, Third Schedule · ASEAN Cosmetic Directive annexes — release 2026-1, 22 June 2026 | ||
| No explicit cap | ||
Brunei carries the 2007 ASEAN annexes in its own schedule and has not updated them since, so it reads differently from Singapore on several ingredients. Medicines (Cosmetic Products) Regulations (Cap. 285 Rg 1), Schedule 1 — revised edition 2024 | ||
| No explicit cap | ||
Jordan's cosmetic rules defer to "the approved references" and name none of them, so there is no Jordanian figure to read. The only number in the instrument governs the ingredient list on the pack. JFDA instructions on cosmetics and pharmaceutical cosmetics, 2026 | ||
| No explicit cap | ||
Trinidad and Tobago has had the power to set cosmetic standards since 1960 and has never used it. The regulations made under the Act cover food and drugs, with no cosmetics part; what binds is the Act's general rule against selling a cosmetic that may injure the user. Food and Drugs Act, Chap. 30:01 · Food and Drugs Regulations | ||
No cosmetic regulator in the 20 markets above sets a maximum strength for purslane. That is the state of the rules, not a signal to use more: how much goes into a product is the formulator's decision.
Open a market to see the rulebook its figure comes from. Those notes describe each market's own rules as we read them, current to August 24, 2026; the linked documents are the authority, and nothing here is legal advice.
Common questions about Purslane#
When should you apply Purslane?
- Morning or evening. Morning or evening — nothing in the record restricts it to one end of the day, and it does not make skin more sensitive to daylight.
How often can you use Purslane?
- Daily.
Where do you apply Purslane?
- All over the face. Keep it away from your eyes and lips.
Does Purslane make skin more sensitive to the sun?
- No. Purslane is not flagged as increasing sun sensitivity.
What should you not use with Purslane?
- Nothing flagged. None of the ingredients this wiki covers needs to be kept apart from Purslane — check the label of anything not covered here.
Who should avoid Purslane?
- Go slowly with Maternity & Nursing.
Is there a cosmetic limit for Purslane?
- No. No cosmetic regulator in the United States, Canada, the European Union or Great Britain sets a maximum strength for it. That is a limit on the rules, not a signal to use more.
Related ingredients#
How we check this#
Everything on this page traces to the sources listed below — regulators' own publications and published studies. Where the evidence does not answer a question, it is left unanswered.
Some sources below are medical studies. This ingredient has been studied in conditions a doctor treats, and the record cited here includes findings that did not favour it. We use those studies for their safety and handling detail only. A cosmetic product is not a medicine and is not intended to treat, cure or prevent any condition.
Some sources below are the official product information for prescription medicines — some contain this ingredient at higher strengths, others are cited for how they interact with it. We use them for their safety and handling detail only. A cosmetic product is not one of those medicines and is not intended to treat any condition.
Our review is AI-assisted and is not a named expert's opinion. Last reviewed September 3, 2026.
Think something here is out of date or wrong? Email us at wiki@skinintelligence.ai with your reasoning and where you read it. We read what people send, and we update the page when the sources support it.
Regulators and official bodies · 13
- S1Cosmetic Ingredient Review Expert Panel for Cosmetic Ingredient Safety. Safety Assessment of Portulaca oleracea-Derived Ingredients as Used in Cosmetics. Final Report, released 11 October 2022 (Panel meeting 26–27 September 2022).
- S2European Commission. CosIng — PORTULACA OLERACEA EXTRACT, entry 59023 (CAS 90083-07-1, EC 290-201-1). Tier 1..
- S3European Commission. CosIng — LACTOBACILLUS/PORTULACA OLERACEA FERMENT EXTRACT, entry 85654. Tier 1..
- S4Commission Decision (EU) 2019/701 of 5 April 2019 establishing a glossary of common ingredient names for use in the labelling of cosmetic products. CELEX 32019D0701. Tier 1..
- S5Regulation (EC) No 1223/2009 of the European Parliament and of the Council on cosmetic products, consolidated text of 18.05.2026, Annexes II–VI. CELEX 02009R1223-20260518.
- S6Health Canada. Cosmetic Ingredient Hotlist: List of Ingredients that are Prohibited for Use in Cosmetic Products / List of Ingredients that are Restricted for Use in Cosmetic Products, 2025. Tier 1..
- S721 CFR part 700, subpart B — Requirements for Specific Cosmetic Products. eCFR current. Tier 1..
- S8The Product Safety and Metrology etc. (Amendment etc.) (EU Exit) Regulations 2019, SI 2019/696, Schedule 34 (amendment of Regulation (EC) No 1223/2009). Tier 1..
- S27Treclin 1%/0.025% w/w Gel (clindamycin / tretinoin) — Summary of Product Characteristics, emc product 5371. Tier 1..
- S28Roaccutane 20 mg soft capsules (isotretinoin) — Summary of Product Characteristics, emc product 100634. Tier 1..
- S33Assimilated Regulation (EC) No 1223/2009, Annex II (GB), legislation.gov.uk.
- S34Assimilated Regulation (EC) No 1223/2009, Annex III (GB), legislation.gov.uk.
- S36Efracea 40 mg Modified Release Hard Capsules (doxycycline) — Summary of Product Characteristics, emc product 6652.
Studies and references · 24
- S9Heydarirad G, Rastegar S, Haji-Abdolvahab H, Fuzimoto A, Hunter J, Zare R, Pasalar M. Efficacy and safety of purslane (Portulaca oleracea) for mild to moderate chronic hand eczema; a randomized, double-blind, placebo-controlled clinical trial. Explore (NY). 2024;20(3):401–410. PMID 37872023. doi:10.1016/j.explore.2023.10.005 — oral syrup, topical arm was Vaseline in both groups..
- S10Niazi A, Yousefzadeh S, Rakhshandeh H, Esmaily H, Askari VR. Promising effects of purslane cream on the breast fissure in lactating women: A clinical trial. Complement Ther Med 2019;43:300–305. PMID 30935548. doi:10.1016/j.ctim.2019.02.002. Tier 2..
- S11Cheng D, Yuan Y, Wang F. Low-temperature extracted Portulaca oleracea L. as a functional ingredient in facial masks for photorejuvenation of sensitive skin. Cutan Ocul Toxicol 2025;44(4):570–578. PMID 41182319. doi:10.1080/15569527.2025.2579937. Tier 2..
- S12Wei J, Quan Q, Wang P, Wang Y, Huo T, An Q. Portulaca oleracea extract relieves skin barrier damage induced by increased photosensitivity after GA peeling. Cutan Ocul Toxicol 2022;41(3):257–263. PMID 35920724. doi:10.1080/15569527.2022.2109658. Tier 2..
- S13Wang Y, Viennet C, Jeudy A, Fanian F, He L, Humbert P. Assessment of the efficacy of a new complex antisensitive skin cream. J Cosmet Dermatol 2018;17(6):1101–1107. PMID 29356277. doi:10.1111/jocd.12486. Tier 2..
- S14Du Z, Ren L, Liang H, Lu Y, Zhang D, Li Z, Wang S, Zhang K, Wu Y, Li D, Ye L, Jiang N. A Split-Face Randomized Study on the Efficacy of a Platinum-Liposome-Based Facial Mask Containing Soothing Ingredients for Post-Photorejuvenation Skin Recovery. J Cosmet Dermatol 2025. PMID 40957858. doi:10.1111/jocd.70452. Tier 2..
- S15Lee S, Kim KH, Park C, Lee JS, Kim YH. Portulaca oleracea extracts protect human keratinocytes and fibroblasts from UV-induced apoptosis. Exp Dermatol 2014;23 Suppl 1:13–17. PMID 25234830. doi:10.1111/exd.12396. Tier 2..
- S16Oh JH, Karadeniz F, Lee JI, Seo Y, Kong CS. Oleracone C from Portulaca oleracea attenuates UVB-induced changes in matrix metalloproteinase and type I procollagen production via MAPK and TGF-β/Smad pathways in human keratinocytes. Int J Cosmet Sci 2023;45(2):166–176. PMID 36415152. doi:10.1111/ics.12828. Tier 2..
- S17Tao X, Hu X, Wu T, Zhou D, Yang D, Li X, Fu Y, Zheng F, Yue H, Dai Y. Characterization and screening of anti-melanogenesis and anti-photoaging activity of different enzyme-assisted polysaccharide extracts from Portulaca oleracea L. Phytomedicine 2023;116:154879. PMID 37229889. doi:10.1016/j.phymed.2023.154879. Tier 2..
- S18Zhao W, Zhang Y, Li W, Hu Q, Huang H, Xu X, Du B, Li P. Probiotic-fermented Portulaca oleracea L. alleviated DNFB-induced atopic dermatitis by inhibiting the NF-κB signaling pathway. J Ethnopharmacol 2023;313:116613. PMID 37156447. doi:10.1016/j.jep.2023.116613. Tier 2..
- S19Alves Barros AS, Oliveira Carvalho H, Dos Santos IVF, Taglialegna T, Dos Santos Sampaio TI, Duarte JL, Fernandes CP, Tavares Carvalho JC. Study of the non-clinical healing activities of the extract and gel of Portulaca pilosa L. in skin wounds in wistar rats: A preliminary study. Biomed Pharmacother 2017;96:182–190. PMID 28987941. doi:10.1016/j.biopha.2017.09.142. Tier 2. (P. pilosa — do not read across.).
- S20Baurin N, Arnoult E, Scior T, Do QT, Bernard P. Preliminary screening of some tropical plants for anti-tyrosinase activity. J Ethnopharmacol 2002;82(2-3):155–158. PMID 12241990. Tier 2. (P. pilosa — do not read across.).
- S21Wei H, Chen Z, Lai W, Wang W, Bian X, Zhang L, Li X. Aqueous extracts of Portulaca oleracea L. alleviate atopic dermatitis by restoring skin barrier function. Front Pharmacol 2025;16:1591394. PMID 40538548. doi:10.3389/fphar.2025.1591394. Tier 2..
- S22Qu L, Wang F, Ma X. The extract from Portulaca oleracea L. rehabilitates skin photoaging via adjusting miR-138-5p/Sirt1-mediated inflammation and oxidative stress. Heliyon 2023;9(11):e21955. PMID 38034793. doi:10.1016/j.heliyon.2023.e21955. Tier 2..
- S23Li K, Xia T, Jiang Y, Wang N, Lai L, Xu S, Yue X, Xin H. A review on ethnopharmacology, phytochemistry, pharmacology and potential uses of Portulaca oleracea L. J Ethnopharmacol 2024;319(Pt 2):117211. PMID 37739100. doi:10.1016/j.jep.2023.117211. Tier 2..
- S24Rahimi VB, Ajam F, Rakhshandeh H, Askari VR. A Pharmacological Review on Portulaca oleracea L.: Focusing on Anti-Inflammatory, Anti-Oxidant, Immuno-Modulatory and Antitumor Activities. J Pharmacopuncture 2019;22(1):7–15. PMID 30988996. doi:10.3831/KPI.2019.22.001. Tier 2..
- S25Zhao J, Zhou B, Hou Y, Li L, Zhuo F. Effect of 5% glycolic acid complex and 20% glycolic acid on mild-to-moderate facial acne vulgaris. Chin Med J (Engl) 2022. PMID 36583924; PMC9943832. doi:10.1097/CM9.0000000000002287. Tier 2..
- S26Allergic Contact Dermatitis to Kojic Acid. Case report, Actas Dermo-Sifiliográficas. Authors could not be confirmed from the capture and are therefore not attributed. Tier 2..
- S29Wang L, Zhang Y, Geng S, Ma L, Wang Y, Han D, Fan G, Zhang W, Lv Y, Ma J. A Chinese drug-compatibility-based approach to purslane hydrogels for acute eczema therapy. Front Pharmacol 2025;16:1504120. PMID 39981178. doi:10.3389/fphar.2025.1504120. Tier 2..
- S30Chan K, Islam MW, Kamil M, Radhakrishnan R, Zakaria MN, Habibullah M, Attas A. The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. Sativa (Haw.) Celak. J Ethnopharmacol 2000;73(3):445–451. PMID 11090998. Tier 2..
- S31Calvo MM, Tzamourani A, Martínez-Alvarez O. Halophytes as a potential source of melanosis-inhibiting compounds. Mechanism of inhibition of a characterized polyphenol extract of purslane (Portulaca oleracea). Food Chem. 2021;355:129649. PMID 33799263. — shrimp diphenol oxidase, food preservation..
- S32Shobeiri SF, Sharei S, Heidari A, Kianbakht S. Portulaca oleracea L. in the treatment of patients with abnormal uterine bleeding: a pilot clinical trial. Phytother Res 2009;23(10):1411–1414. PMID 19274703. doi:10.1002/ptr.2790. Tier 2..
- S35Zhao H, Li S, Luo F, Tan Q, Li H, Zhou W. Portulaca oleracea L. aids calcipotriol in reversing keratinocyte differentiation and skin barrier dysfunction in psoriasis through inhibition of the nuclear factor κB signaling pathway. Exp Ther Med. 2015. PMID 25574190; PMC4280941.
- S37Parry O, Okwuasaba F, Ejike C. Preliminary clinical investigation into the muscle relaxant actions of an aqueous extract of Portulaca oleracea applied topically. J Ethnopharmacol. 1987;21(1):99–106. PMID 3695561.



